Yolanda Colino-Sanguino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yolanda Colino-Sanguino has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Fatima Valdes-Mora
School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Sydney, Australia
21 shared publications - Ron Firestein
Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, VIC 3168, Australia
16 shared publications - Abdul Mannan
Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia
15 shared publications - Adjanie Patabendige
Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom
15 shared publications - Alicia M. Douglas
Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia
15 shared publications - Andria Rakotomalala
25Tumorigenesis and Resistance to Treatment Unit, Centre Oscar Lambret, Lille, France
15 shared publications
Latest Publications
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
All Supplementary Figures and their captions.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
All Supplementary Figures and their captions.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
- Open Access
Androgen stimulation rapidly reorganizes temporal 3D genome and epigenome states to trigger AR-mediated transcription in prostate cancer
Androgen receptor (AR)-mediated transcription drives prostate cancer progression and remains a critical therapeutic target. AR activation by androgens triggers nuclear translocation, DNA binding at AR regulatory elements (AREs) and transcription initiation. This process involves co-factors such as FOXA1, epigenetic modifications, and 3D chromatin interactions. However, the temporal coordination of these events during AR-mediated transcription remains poorly understood. Using a time-course androgen stimulation model in prostate cancer cells, we integrated temporal multi-omics data within the MOFA+ framework to dissect AR-mediated transcriptional dynamics. Our analysis revealed that rapid AR binding at gene promoters is crucial for initiating nascent transcription of AR target genes. We identified H3K27 acetylation at flanking AREs, pre-marked by constitutive FOXA1 binding, occurs prior to AR recruitment. Additionally, androgen stimulation induced a temporal early shift in nascent transcription from MYC to AR target genes, associated with transient disruption of 3D chromatin interactions. Finally, we showed that CRISPR-mediated inhibition of AR-associated chromatin contacts suppresses distal linked target genes, demonstrating that dynamic genome architecture is functionally required for AR-driven transcription. Together these findings uncover the dynamic reorganization of 3D chromatin structure and transcription factor binding post-androgen stimulation, resulting in distinct temporal epigenomic states. This work provides new insights into the mechanisms governing AR-mediated transcriptional activation in prostate cancer and highlights the interplay between MYC and AR in regulating transcription in hormone-driven cancers.
Open AccessAndrogen stimulation rapidly reorganizes temporal 3D genome and epigenome states to trigger AR-mediated transcription in prostate cancer
Androgen receptor (AR)-mediated transcription drives prostate cancer progression and remains a critical therapeutic target. AR activation by androgens triggers nuclear translocation, DNA binding at AR regulatory elements (AREs) and transcription initiation. This process involves co-factors such as FOXA1, epigenetic modifications, and 3D chromatin interactions. However, the temporal coordination of these events during AR-mediated transcription remains poorly understood. Using a time-course androgen stimulation model in prostate cancer cells, we integrated temporal multi-omics data within the MOFA+ framework to dissect AR-mediated transcriptional dynamics. Our analysis revealed that rapid AR binding at gene promoters is crucial for initiating nascent transcription of AR target genes. We identified H3K27 acetylation at flanking AREs, pre-marked by constitutive FOXA1 binding, occurs prior to AR recruitment. Additionally, androgen stimulation induced a temporal early shift in nascent transcription from MYC to AR target genes, associated with transient disruption of 3D chromatin interactions. Finally, we showed that CRISPR-mediated inhibition of AR-associated chromatin contacts suppresses distal linked target genes, demonstrating that dynamic genome architecture is functionally required for AR-driven transcription. Together these findings uncover the dynamic reorganization of 3D chromatin structure and transcription factor binding post-androgen stimulation, resulting in distinct temporal epigenomic states. This work provides new insights into the mechanisms governing AR-mediated transcriptional activation in prostate cancer and highlights the interplay between MYC and AR in regulating transcription in hormone-driven cancers.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
All Supplementary Figures and their captions.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
All Supplementary Figures and their captions.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
All Supplementary Figures and their captions.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
All Supplementary Figures and their captions.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
- Open Access
Chromatin remodeling with combined FACT and BET inhibition disrupts oncogenic transcription in Diffuse Midline Glioma
Aberrant epigenetic regulation is a hallmark of Diffuse Midline Glioma (DMG), an incurable pediatric brain tumor. The H3K27M driver histone mutation leads to transcriptional dysregulation, indicating that targeting the epigenome and transcription may be key therapeutic strategies against this highly aggressive cancer. One such target is the Facilitates Chromatin Transcription (FACT) histone chaperone. We found FACT to be enriched at developmental gene promoters, coinciding with regions of open chromatin and binding motifs of core DMG regulatory transcription factors. Furthermore, FACT interacted and co-localized with the Bromodomain and Extra-Terminal Domain (BET) protein BRD4 at promoters and enhancers, suggesting functional cooperation between FACT and BRD4 in DMG. In vitro , a combinatorial therapeutic approach using the FACT inhibitor CBL0137, coupled with BET inhibition revealed potent and synergistic cytotoxicity across a range of DMG cultures. These results were recapitulated in vivo , significantly extending survival in three independent orthotopic PDX models of DMG. Mechanistically, we show that CBL0137 treatment decreased chromatin accessibility, synergizing with BET inhibition to cause broad transcriptional collapse, silencing several key oncogenes including MYC, PDGFRA , MDM4 and SOX2 , as well as causing alterations to the splicing landscape. Notably, this combination also elicited immune-related effects, including activation of the interferon response and antigen presentation mechanisms in DMG cells and induction of an activated state in macrophages and T cells, as demonstrated in an immunocompetent setting with spatial transcriptomics. Altogether, our data highlights the therapeutic promise of simultaneously targeting FACT and BET proteins in DMG, offering a dual tumor-intrinsic and immune-mediated strategy for combating this devastating pediatric brain tumor.
Open AccessChromatin remodeling with combined FACT and BET inhibition disrupts oncogenic transcription in Diffuse Midline Glioma
Aberrant epigenetic regulation is a hallmark of Diffuse Midline Glioma (DMG), an incurable pediatric brain tumor. The H3K27M driver histone mutation leads to transcriptional dysregulation, indicating that targeting the epigenome and transcription may be key therapeutic strategies against this highly aggressive cancer. One such target is the Facilitates Chromatin Transcription (FACT) histone chaperone. We found FACT to be enriched at developmental gene promoters, coinciding with regions of open chromatin and binding motifs of core DMG regulatory transcription factors. Furthermore, FACT interacted and co-localized with the Bromodomain and Extra-Terminal Domain (BET) protein BRD4 at promoters and enhancers, suggesting functional cooperation between FACT and BRD4 in DMG. In vitro , a combinatorial therapeutic approach using the FACT inhibitor CBL0137, coupled with BET inhibition revealed potent and synergistic cytotoxicity across a range of DMG cultures. These results were recapitulated in vivo , significantly extending survival in three independent orthotopic PDX models of DMG. Mechanistically, we show that CBL0137 treatment decreased chromatin accessibility, synergizing with BET inhibition to cause broad transcriptional collapse, silencing several key oncogenes including MYC, PDGFRA , MDM4 and SOX2 , as well as causing alterations to the splicing landscape. Notably, this combination also elicited immune-related effects, including activation of the interferon response and antigen presentation mechanisms in DMG cells and induction of an activated state in macrophages and T cells, as demonstrated in an immunocompetent setting with spatial transcriptomics. Altogether, our data highlights the therapeutic promise of simultaneously targeting FACT and BET proteins in DMG, offering a dual tumor-intrinsic and immune-mediated strategy for combating this devastating pediatric brain tumor.
- Open Access
- 14 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
All Supplementary Figures and their captions.
- 14 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
All Supplementary Figures and their captions.
- Open Access
- 14 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
- 14 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma